Santa Clara, CA & San Francisco, CA, March 9, 2026 (Business Wire) -- Agilent Technologies announced it has agreed to acquire Biocare Medical for $950 million in cash, expanding its portfolio in clinical and research pathology solutions. Biocare develops antibodies, reagents, and instruments used in technologies such as immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH), and generated over $90 million in revenue in 2025 wh

Dedham, MA, March 1, 2026 (Business Wire) -- Qlaris Bio has appointed Fred Guerard, Pharm.D., as president and chief executive officer, effective March 1, 2026, and he will also join the company’s board of directors. Guerard brings more than 20 years of leadership experience in ophthalmology and biotechnology, with a focus on advancing innovative therapies through late-stage development and commercialization. He succeeds Thurein Htoo, who helped establish the company and ad

Suresnes, France & Brisbane, CA, March 6, 2026 (Globe Newswire) -- Servier has agreed to acquire Day One Biopharmaceuticals for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The acquisition strengthens Servier’s rare oncology portfolio, particularly in pediatric low-grade glioma, and adds several oncology programs spanning early development through Phase 3. The transaction, expected to close in the second quarter of 2026, combine

Copenhagen, March 4, 2026 (Coloplast) -- Coloplast has appointed Gavin Wood as President and Chief Executive Officer, effective May 1, 2026, succeeding interim CEO Lars Rasmussen. Wood joins after more than 20 years at Johnson & Johnson, most recently serving as Company Group Chairman of Johnson & Johnson MedTech EMEA, overseeing a multi-billion-dollar business spanning surgery, orthopedics, and cardiovascular solutions. He will relocate to Denmark as he takes over leadersh

Dublin, Ireland, March 10, 2026 (Reuters) -- Medtronic announced plans to acquire Scientia Vascular for approximately $550 million, expanding its portfolio of devices used to treat stroke. The Salt Lake City–based company develops specialized guidewires and catheters designed to navigate delicate blood vessels in the brain, technologies that will integrate with Medtronic’s existing neurovascular product line. The transaction, expected to close in the first half of fiscal 20

London, February 25, 2026 (Proactive) -- GSK has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, adding a clinical-stage pulmonary hypertension therapy to its pipeline. The company believes the drug could offer a safer alternative to existing treatments, which are often limited by bleeding complications. The global pulmonary hypertension market is projected to reach $18 billion by 2032. The centerpiece of the deal is HS235, an activin signaling inhibit

Boca Raton, FL, February 18, 2026 (Globe Newswire) -- LIXTE Biotechnology Holdings, Inc., a clinical-stage oncology company developing small-molecule cancer therapies and radiotherapy technologies, announced the appointment of Sidney Braun as Chief Executive Officer of its European subsidiary, Liora Technologies Europe Ltd.. Braun brings more than two decades of healthcare operational and strategic experience and previously played a key role in establishing Liora and facili

Waltham, MA, February 18, 2026 (Business Wire) -- Korsana Biosciences announced it has emerged from stealth mode with $175 million in total funding to advance novel therapies for neurodegenerative diseases, initially focusing on Alzheimer’s disease. The financing includes a $25 million seed round in 2024 led by Fairmount and Venrock Healthcare Capital Partners, followed by a $150 million Series A in September 2025 co-led by Wellington Management and TCGX, with participation

Paris, February 12, 2026 (Sanofi) -- Sanofi has named Belen Garijo as its next Chief Executive Officer, following the Board’s decision not to renew Paul Hudson’s mandate. Hudson will step down on February 17, 2026, after six years leading the company’s strategic transformation. Garijo will officially assume the CEO role after the Annual General Meeting on April 29, 2026, subject to shareholder approval of her nomination to the Board. During the interim period, Olivier Charm

Washington, February 17, 2026 (PRNewswire) -- Danaher Corporation announced it has signed a definitive agreement to acquire Masimo Corporation, a leader in pulse oximetry and advanced patient monitoring technologies, in an all-cash deal valued at approximately $9.9 billion, including assumed debt. Under the agreement, Danaher will pay $180 per share in cash, representing a transaction multiple of roughly 18x estimated 2027 EBITDA, or 15x including expected synergies. Masimo

Franklin Lakes, NJ, February 9, 2026 (PRNewswire) -- BD said it has completed the spin-off of its Biosciences & Diagnostic Solutions business and combined it with Waters Corporation, finalizing the previously announced transaction. At closing, BD shareholders received Waters shares representing 39.2% of the combined company (fully diluted), and BD said the business was valued at $18.8B based on Waters’ Feb. 6, 2026 closing price. BD also said it plans to deploy $2B toward a

Boston and Toronto, February 10, 2026 (Globe Newswire) -- Helus Pharma named Michael Cola Chief Executive Officer, effective immediately, as the company shifts into a “scale and execution” phase. Cola previously led Shire’s Specialty Pharmaceutical business and brings 30+ years across neuroscience, rare disease, and specialty pharma, with experience spanning late-stage development and global commercialization. The company said the timing aligns with upcoming milestones, inc